University of Lille, F-59000 Lille, France.
University of Lille, F-59000 Lille, France.
Eur J Obstet Gynecol Reprod Biol. 2024 Dec;303:212-217. doi: 10.1016/j.ejogrb.2024.10.047. Epub 2024 Oct 29.
To assess symptom resolution and patient satisfaction following surgical explantation of Essure implants in the short and long term.
Retrospective monocentric cohort study (Lille Regional University Hospital, France).
Essure is an implantable medical device for definitive sterilisation. Available from 2002, the Essure device has no longer been marketed since 2017. Following numerous reported side effects, the number of requests to withdraw Essure has steadily increased in recent years.
All women who underwent Essure removal between December 2016 and January 2020 to assess the benefits of surgery on these symptoms and patient satisfaction at 6 weeks and 6 months after the procedure.
Removal of Essure implant with 4 types of surgery.
The benefits of the surgery were assessed using data from the postoperative consultation 6 to 8 weeks after surgery and then from a telephone call 6 months after surgery.
86 patients were explanted during the study period. Surgery proved beneficial, with a complete reduction in symptoms at 6 months in 74 % of these patients. Many symptoms were relieved by surgery, with complete resolution of symptoms in 62 % of cases for muscle pain, in 69 % of cases for asthenia, in 82 % of cases for abdominal pain and 100 % of cases for menorrhagia. Patient satisfaction was high, with 97.3 % of patients willing to repeat the procedure and 95.95 % recommending it to a friend.
Removal of Essure implants in symptomatic patients appears to reduce all symptoms and improve quality of life in short and long term. Nevertheless, there are many symptoms associated with the insertion of Essure implants, and although surgery appears beneficial with good patient compliance, some adverse effects persist. It is therefore important to carry out a pre-operative etiological assessment and provide information on the risk of surgical failure.
评估 Essure 植入物短期和长期手术取出后症状缓解和患者满意度。
回顾性单中心队列研究(法国里尔地区大学医院)。
Essure 是一种用于永久性绝育的可植入医疗器械。自 2002 年上市以来,Essure 装置自 2017 年以来已不再销售。由于报告了许多不良副作用,近年来要求取出 Essure 的数量稳步增加。
所有于 2016 年 12 月至 2020 年 1 月期间接受 Essure 取出术的女性,以评估手术对这些症状的益处以及术后 6 周和 6 个月时的患者满意度。
采用 4 种手术方式取出 Essure 植入物。
术后 6 至 8 周的术后咨询和术后 6 个月的电话随访中评估手术的益处。
研究期间共 86 例患者接受了手术。手术证明是有益的,74%的患者在术后 6 个月时症状完全缓解。许多症状通过手术得到缓解,62%的患者肌肉疼痛完全缓解,69%的患者乏力,82%的患者腹痛,100%的患者月经过多完全缓解。患者满意度高,97.3%的患者愿意再次接受该手术,95.95%的患者会向朋友推荐该手术。
在有症状的患者中取出 Essure 植入物似乎可以减轻所有症状,并在短期和长期内提高生活质量。然而,Essure 植入物的插入与许多症状相关,尽管手术在患者依从性好的情况下似乎有益,但一些不良影响仍然存在。因此,在术前进行病因评估并提供有关手术失败风险的信息非常重要。